NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, will deliver two poster presentations at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. The two poster presentations will describe results from new studies of NVC-422, an Aganocide(R) compound.
Presentation details are as follows:
Poster Title: N,N-dichloro-2,2-dimethyltaurine (NVC-422) has bactericidal activity against antiseptic and antibiotic-resistant
Staphylococcus aureus Date/Time: Monday September 14, from 11:15 am to 1:15 pm (Pacific Time) Session: 163. Miscellaneous Abstract Number: E-1468 Location: Hall B Poster Title: Antimicrobial activity of endogenous and stabilized derivatives of N-chlorotaurines against representative microorganisms in the presence of human plasma, serum and albumin Date/Time: Monday September 14, from 11:15 am to 1:15 pm (Pacific Time) Session: 167-New Topical Antibacterial Agents Including Agents against C. difficile Abstract Number: F1-1526 Location: Hall B
"These findings support the compelling therapeutic profile of NVC-422 as a broad spectrum antimicrobial agent that carries little potential for resistance through common antiseptic resistance mechanisms," said Dr. Dmitri Debabov, poster co-author and assistant director of microbiology and acting head of biology of NovaBay Pharmaceuticals.
About Aganocide Compounds